Arca
Skip to content
Tools
Tools

CYP19A1: Aromatase

A cytochrome P450 monooxygenase that catalyzes the conversion of C19 androgens, androst-4-ene-3,17-dione (androstenedione) and testosterone to the C18 estrogens, estrone and estradiol, respectively.

  • Drugs that act on it: 6
  • Approved: 5
  • In phases 1 to 3: 1
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on CYP19A1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 6

Approved5

  • Letrozole
  • Anastrozole
  • Exemestane
  • Aminoglutethimide
  • Testolactone

Phase 30

    Phase 21

    • Fadrozole

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Cytochrome P450 19A1 inhibitor.
      LetrozoleApprovedNovartis PharmaceuticalsSmall moleculeInhibitor271
      AnastrozoleApprovedANI PharmaceuticalsSmall moleculeInhibitor141
      ExemestaneApprovedPfizerSmall moleculeInhibitor118
      AminoglutethimideApprovedNovartis PharmaceuticalsSmall moleculeInhibitor0
      TestolactoneApprovedBristol-Myers SquibbSmall moleculeInhibitor0
      FadrozolePhase 2—Small moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
      KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast CancerExemestanePhase 2Not yet recruitingBeijing Konruns Pharmaceutical Co., Ltd.Nov 16, 2026
      A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerAnastrozole, Exemestane, LetrozolePhase 2Not yet recruitingEli Lilly and CompanyNov 13, 2026
      A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsLetrozolePhase 1RecruitingChengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.Nov 6, 2026
      A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.LetrozolePhase 2RecruitingThe First Affiliated Hospital with Nanjing Medical UniversityOct 28, 2026
      A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid TumorsLetrozolePhase 1Not yet recruitingPfizerOct 27, 2026
      A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast CancerAnastrozole, LetrozolePhase 3Not yet recruitingJiangsu HengRui Medicine Co., Ltd.Oct 26, 2026
      A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast CancerLetrozolePhase 1Not yet recruitingGenentech, Inc.Oct 9, 2026
      De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast CancerLetrozolePhase 2Not yet recruitingMontefiore Medical CenterOct 8, 2026
      Sequential vs. Combined Letrozole and Methotrexate for Tubal Ectopic Pregnancy.LetrozolePhase 2 / Phase 3Active, not recruitingBenha UniversitySep 25, 2026
      Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerAnastrozole, ExemestanePhase 2Not yet recruitingFudan UniversitySep 17, 2026
      Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast CancerAnastrozole, ExemestanePhase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologySep 9, 2026
      Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerAnastrozole, ExemestanePhase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySep 1, 2026
      QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyAnastrozole, ExemestanePhase 2Not yet recruitingHebei Medical University Fourth HospitalAug 24, 2026
      Tai Chi for Reducing Aromatase Inhibitor-Induced ArthralgiaExemestaneNot applicableRecruitingThomas Jefferson UniversityJul 30, 2026
      Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerAnastrozole, ExemestanePhase 2Not yet recruitingUniversity of California, San DiegoJul 27, 2026
      Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerAnastrozolePhase 2Not yet recruitingFudan UniversityJul 21, 2026

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Aromatase deficiency0.79
      • Breast carcinoma0.63
      • Aromatase excess syndrome0.63
      • Neoplasm0.56
      • Endometrial carcinoma0.48
      • Breast hypertrophy0.42

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1978, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P11511, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.